List of Excipients in Branded Drug BUPAP

Generic Drugs Containing BUPAP

Company	Ingredient	NDC	Excipient
Bausch Health US LLC	butalbital and acetaminophen tablets	0095-3000	CELLULOSE, MICROCRYSTALLINE
Bausch Health US LLC	butalbital and acetaminophen tablets	0095-3000	CROSCARMELLOSE SODIUM
Bausch Health US LLC	butalbital and acetaminophen tablets	0095-3000	D&C YELLOW NO. 10
Bausch Health US LLC	butalbital and acetaminophen tablets	0095-3000	FD&C RED NO. 40
Bausch Health US LLC	butalbital and acetaminophen tablets	0095-3000	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in BUPAP?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	D&C YELLOW NO. 10
1	FD&C RED NO. 40
1	MAGNESIUM STEARATE

BUPAP Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

BUPAP is an oral immediate-release combination of butalbital and acetaminophen used for tension headache. Its commercial profile is shaped by an old, highly substitutable product, limited differentiation, acetaminophen hepatotoxicity risk, controlled-substance requirements for butalbital, and a mature generic market. The strongest opportunities are in reliable supply, improved tablet performance, patient-use safeguards, and differentiated delivery formats rather than broad patent exclusivity.

What is BUPAP and how is it regulated?

BUPAP contains butalbital and acetaminophen in an immediate-release tablet. The commonly marketed strength is 50 mg of butalbital and 300 mg of acetaminophen per tablet. Butalbital is a barbiturate central nervous system depressant, while acetaminophen provides analgesic activity.

Attribute	BUPAP
Active ingredients	Butalbital and acetaminophen
Common strength	50 mg / 300 mg
Dosage form	Immediate-release oral tablet
Therapeutic use	Tension headache
Regulatory pathway	Legacy approved product with generic competition
Controlled-substance status	Butalbital-containing products are subject to federal and state controlled-substance requirements
Main safety constraints	Sedation, dependence, medication-overuse headache, acetaminophen liver toxicity
Primary commercial competitors	Generic butalbital/acetaminophen tablets, Fioricet and generic butalbital/acetaminophen/caffeine products, other headache therapies

The FDA labeling states that BUPAP should be used cautiously because butalbital can produce dependence and acetaminophen can cause severe liver injury at excessive total daily doses or in patients using other acetaminophen-containing products.[1]

BUPAP is not a biologic and has no biosimilar pathway. The relevant competitive pathway is generic substitution through an abbreviated new drug application, or ANDA. A materially reformulated product may instead require a 505(b)(2) application, depending on the nature of the change and the sponsor's reliance on existing FDA findings.

What excipients are used in BUPAP tablets?

The precise inactive-ingredient composition depends on the manufacturer and marketed NDC. BUPAP and generic equivalents can use conventional immediate-release tablet excipients such as:

• Microcrystalline cellulose
• Pregelatinized starch or other disintegrant systems
• Povidone or another binder
• Croscarmellose sodium
• Colloidal silicon dioxide
• Magnesium stearate
• Coloring agents
• Sodium lauryl sulfate or another wetting agent, where needed

The excipient system must support content uniformity for a low-dose, potent active ingredient, rapid disintegration, acceptable hardness, low friability, and stable acetaminophen performance.

Butalbital is present at a relatively low dose compared with acetaminophen. That creates a blend-uniformity and segregation risk during manufacturing. The formulation must prevent butalbital-rich or butalbital-poor tablets, particularly when direct compression is used.

What formulation functions matter most?

Formulation function	Commercial and technical objective
Dilution	Increase blend volume and improve content uniformity
Binding	Produce tablets with adequate mechanical strength
Disintegration	Support immediate release and generic bioequivalence
Lubrication	Enable ejection without slowing dissolution excessively
Glidancy	Improve powder flow and reduce weight variation
Wetting	Support uniform granulation and dissolution
Color and appearance	Maintain product identification and reduce medication errors
Moisture control	Protect tablet hardness, dissolution, and chemical stability

A conventional wet-granulation process can reduce segregation and improve uniformity, but it adds processing steps and potential moisture exposure. Direct compression can reduce manufacturing cost and improve throughput, but it requires tightly controlled particle-size distribution and flow properties.

How should an excipient strategy be designed for BUPAP?

The preferred strategy is a low-complexity, immediate-release platform with strong process controls. Reformulation should target manufacturability, dose consistency, and patient handling rather than a dramatic release-profile change.

1. Optimize low-dose content uniformity

Butalbital distribution is the principal blend-design issue. Useful approaches include:

• Selecting a directly compressible butalbital premix
• Matching active and excipient particle-size distributions
• Using geometric dilution during blending
• Applying wet granulation when segregation cannot be controlled by direct compression
• Validating blend and tablet content uniformity at commercial scale
• Controlling electrostatic charging during dispensing and compression

A sponsor should avoid unnecessary excipient complexity. Each added excipient increases compatibility, supply, and regulatory-control requirements without necessarily producing a marketable advantage.

2. Balance rapid disintegration against tablet robustness

BUPAP is an immediate-release product. A high-performing formulation should disintegrate rapidly while maintaining:

• Tablet hardness suitable for bottle and blister distribution
• Low friability
• Stable dissolution after accelerated aging
• Resistance to capping and lamination
• Consistent performance across commercial manufacturing sites

Croscarmellose sodium, crospovidone, and sodium starch glycolate are possible disintegrant platforms. The selection should be based on dissolution, compression behavior, moisture sensitivity, and compatibility with the selected binder and lubricant.

Excessive magnesium stearate can slow wetting and dissolution. Lubrication time and concentration therefore require tighter control than the tablet's low-cost profile might suggest.

3. Manage acetaminophen compatibility and stability

Acetaminophen is generally well established in oral solid dosage forms, but stability can be affected by moisture, heat, excipient impurities, and packaging. The sponsor should evaluate:

• Water activity
• Moisture uptake
• Oxidative impurities
• Metal-ion contamination
• Color stability
• Dissolution after storage
• Degradation products under accelerated conditions

Low-moisture excipients and high-barrier packaging can reduce stability risk. A formulation that performs adequately in a bottle may require a different moisture-control strategy in a unit-dose blister.

4. Improve patient identification and administration

Color and imprinting are practical commercial variables. Because BUPAP contains a sedating controlled substance, a clearly identifiable tablet can reduce dispensing and administration errors. Potential design elements include:

• Distinctive tablet color
• Strong debossed imprint
• Unit-dose packaging
• Child-resistant and senior-friendly packaging options
• Separation from similarly shaped acetaminophen products
• Medication-guide and labeling integration

These changes usually create limited patent protection, but they can support a differentiated product presentation and institutional contracting.

What formulation patents protect BUPAP?

The original BUPAP product is an older combination product. Any original formulation, composition, or method-of-use patent rights associated with the legacy product would generally have expired long ago, subject to the specific patent history and any granted extensions.

The commercial protection today is therefore unlikely to depend on a live composition-of-matter patent covering the basic butalbital/acetaminophen tablet. A new sponsor could pursue protection for a genuinely differentiated formulation, such as:

• A controlled-release butalbital system
• A multiparticulate formulation
• A taste-masked liquid or orally disintegrating tablet
• A tamper-resistant dosage form
• A stability-enhanced composition
• A manufacturing process that produces a distinct product profile
• A package-based adherence or dispensing system

Patentability would depend on novelty, non-obviousness, written description, enablement, and claim scope. A generic immediate-release tablet using standard excipients would face a weak patent position unless the composition or process contains a non-obvious technical feature.

What claims are most defensible?

The strongest claims would normally be tied to measurable technical performance:

1. A defined dissolution profile across specified media.
2. A narrow content-uniformity range after scale-up.
3. A specific excipient ratio that prevents segregation.
4. A moisture-stable composition with defined impurity limits.
5. A tamper-resistance result supported by standardized testing.
6. A dosage form that reduces rapid extraction or crushing while preserving intended release.

Broad claims covering "a tablet comprising butalbital, acetaminophen, and a disintegrant" would be vulnerable because the active combination and conventional excipient classes are old and extensively disclosed.

When does BUPAP lose exclusivity?

BUPAP's core commercial exclusivity has already expired. The product is exposed to generic substitution and does not have the exclusivity profile of a recently approved small-molecule product.

Exclusivity category	BUPAP position
New chemical entity exclusivity	Expired or unavailable for this legacy combination
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No current commercial relevance
Biologic exclusivity	Not applicable
Original formulation exclusivity	Expired
Generic substitution risk	High
New reformulation exclusivity	Possible only for a newly approved, differentiated product

A new formulation could receive limited regulatory exclusivity if it qualifies under the applicable FDA pathway, but the sponsor would need to establish a meaningful product distinction. Regulatory exclusivity would not automatically block all generic versions of the underlying immediate-release combination.

What is the Orange Book status of BUPAP?

The FDA Orange Book is relevant to approved drug products and listed patents, but the principal BUPAP commercial issue is not an active legacy patent estate. A sponsor evaluating BUPAP should distinguish among:

• The original BUPAP NDA
• Current marketed BUPAP NDCs
• Generic ANDA products
• Listed patents, if any, associated with a particular approved product
• Discontinued or dormant listings
• Patent certifications submitted by ANDA applicants

Orange Book status can change as products are discontinued, relisted, or transferred among holders. A current transaction or launch decision should rely on the FDA's current electronic Orange Book and Drugs@FDA records rather than historic references.

The practical conclusion is that BUPAP is a generic-exposed product. Any commercial moat must come from formulation performance, supply reliability, distribution, packaging, or a new clinical and regulatory positioning.

Are there Paragraph IV challenges to BUPAP?

Paragraph IV litigation is less likely to create a material barrier for the basic BUPAP product because the relevant legacy rights are old and generic competition is established. ANDA applicants may still submit Paragraph IV certifications against any currently listed patent associated with a branded or reformulated product, but that analysis is product-specific.

For a new BUPAP formulation, Paragraph IV risk would depend on:

• Whether patents are listed in the Orange Book
• Whether claims cover the approved dosage form or method of use
• Whether generic applicants can design around the claims
• Whether the patent owner has enforceable claims after claim construction
• Whether the generic product can launch under a Paragraph III or section viii certification

A sponsor should not assume that an unlisted patent creates the same litigation leverage as an Orange Book-listed patent. Method-of-use claims also have narrower blocking power when generic labels can omit the patented indication or dosing instruction.

What generic entry risks exist for BUPAP?

Generic entry risk is high for any conventional immediate-release BUPAP tablet. The principal entry routes are:

• ANDA approval based on pharmaceutical equivalence and bioequivalence
• Authorized generic supply
• Contract-manufactured private-label products
• Therapeutic substitution toward butalbital/acetaminophen/caffeine products
• Pharmacy switching driven by price and wholesaler availability

A generic applicant can generally use well-established excipients unless the reference product has a clinically relevant formulation attribute that must be replicated. The sponsor must show that inactive ingredients are acceptable and that the product meets applicable quality and bioequivalence requirements.

Potential barriers are practical rather than legal:

• Controlled-substance manufacturing and distribution controls
• Acetaminophen assay and impurity requirements
• Low-dose butalbital uniformity
• Reliable API sourcing
• DEA registration and quota management
• Stability in commercial packaging
• Batch-release testing
• Pharmacovigilance for sedation, dependence, and overdose risk

What commercial opportunities exist for BUPAP excipient innovation?

Cost-focused generic platform

The most immediate opportunity is a cost-optimized generic tablet with robust content uniformity and a simplified excipient system. Competitive advantage could come from:

• Fewer manufacturing steps
• Higher tablet yield
• Lower rejection rates
• Broader supplier qualification
• Reduced lubricant sensitivity
• Faster scale-up
• Stable supply of butalbital API

This is a procurement and operations opportunity rather than a premium brand opportunity.

Premium packaging and unit-dose distribution

Unit-dose blister packaging can support hospitals, correctional facilities, long-term-care providers, and specialty pharmacies. It can improve identification, inventory control, and dispensing documentation. The tradeoff is higher packaging cost and more demanding moisture-barrier requirements.

Orally disintegrating or fast-dispersing dosage form

An orally disintegrating tablet could target patients who have difficulty swallowing. The formulation would need to control:

• Butalbital taste
• Acetaminophen taste
• Tablet friability
• Mouthfeel
• Dose uniformity
• Moisture sensitivity
• Rapid dispersion without unintended absorption changes

Taste masking may require polymer coating, ion-exchange technology, complexation, or flavor systems. A successful product could support a 505(b)(2) strategy, but it would need a defensible clinical and regulatory rationale.

Abuse-deterrent or tamper-resistant design

Because butalbital is a sedative with misuse and dependence potential, a tamper-resistant formulation could create differentiation. Possible technologies include:

• Crush-resistant matrix systems
• Gel-forming polymers
• Sequestration of the active ingredient
• Difficult-to-extract tablet structures
• Physical barriers to pulverization

The commercial case is challenging. Abuse-deterrent labeling requires FDA-recognized evidence, and a formulation that changes immediate-release performance may face substantial bioequivalence and clinical-development requirements. Excipients alone do not support an abuse-deterrent claim.

Acetaminophen exposure management

A formulation cannot eliminate the systemic risk created by total acetaminophen exposure. Commercial opportunities are more credible in packaging and labeling:

• Unit-dose presentation
• Clear maximum daily-dose instructions
• Prominent warnings about combination acetaminophen products
• Dispensing controls
• Patient-specific packaging
• Pharmacy decision-support integration

A lower-acetaminophen-strength product could reduce per-tablet exposure but would require a new product strategy and clinical justification. It could also affect efficacy, adherence, and prescribing behavior.

How does BUPAP compare with Fioricet and other competitors?

Product category	Active ingredients	Differentiation	Generic risk	Excipient opportunity
BUPAP	Butalbital/acetaminophen	No caffeine; legacy tablet	High	Manufacturing, packaging, swallowability
Fioricet	Butalbital/acetaminophen/caffeine	Includes caffeine	High	Caffeine-related taste and stability management
Generic BUPAP	Butalbital/acetaminophen	Price and availability	High	Cost and supply-chain optimization
Non-butalbital headache products	Varies	Different mechanism and safety profile	Product-specific	New delivery systems and adherence formats

BUPAP competes against products with caffeine as well as non-barbiturate headache treatments. Its absence of caffeine can appeal to patients who avoid stimulants, but the product remains constrained by butalbital dependence risk and acetaminophen exposure.

What manufacturing and geographic barriers affect BUPAP?

BUPAP manufacturing is technically accessible, but controlled-substance compliance increases operational complexity. A commercial manufacturer must manage:

• DEA registration and recordkeeping
• Controlled-substance inventory reconciliation
• Secure storage and shipment
• API quota and procurement
• Diversion monitoring
• State controlled-substance requirements
• FDA current good manufacturing practice compliance
• Foreign supplier qualification
• Import and customs controls

Geographic expansion is possible because the active ingredients and tablet technology are established. Regulatory strategy changes by market, however. Butalbital availability and scheduling differ internationally, and a U.S. formulation cannot be assumed to have an equivalent approval route abroad.

What licensing opportunities exist for BUPAP?

There is limited strategic value in licensing the legacy BUPAP brand alone unless the transaction includes one or more of the following:

• An established controlled-substance manufacturing network
• A differentiated formulation
• A regulated-market marketing authorization
• A reliable butalbital API supply arrangement
• An institutional or specialty-pharmacy distribution channel
• A reformulation with patent or regulatory exclusivity potential

The most attractive licensing structure would likely involve a new dosage form or platform technology rather than an assignment of expired legacy rights. Royalty value would depend on evidence that the formulation improves adherence, reduces handling risk, lowers manufacturing cost, or supports a differentiated FDA label.

How strong is the BUPAP patent estate?

The legacy patent estate is weak as a blocking asset because the core active combination and conventional immediate-release tablet are mature. A new patent estate could be moderate if it covers a technically difficult formulation with reproducible performance and limited design-around options.

Asset type	Expected strategic strength
Core butalbital/acetaminophen composition	Low
Conventional immediate-release tablet	Low
Specific excipient ratio	Low to moderate
Process preventing segregation	Moderate if technically demonstrated
Taste-masked orally disintegrating tablet	Moderate
Tamper-resistant formulation	Moderate to strong if validated
Packaging-only claims	Low to moderate
Method-of-use claims	Moderate but indication-dependent

Key Takeaways

• BUPAP is a legacy butalbital/acetaminophen immediate-release tablet with high generic exposure.
• The basic active combination and conventional tablet technology offer little new-patent value.
• The central formulation challenge is uniform distribution of low-dose butalbital within an acetaminophen-heavy tablet.
• A practical excipient strategy should prioritize content uniformity, rapid disintegration, stability, compression performance, and supplier flexibility.
• The strongest commercial opportunities are cost-efficient generic manufacture, unit-dose packaging, swallowability improvements, and carefully validated abuse-deterrent or taste-masked formats.
• Any reformulated product should be assessed under an ANDA or 505(b)(2) strategy before development commitments.
• Butalbital control requirements, acetaminophen safety, and generic substitution are greater commercial constraints than legacy patent expiration.
• Licensing value is more likely to reside in a differentiated formulation, manufacturing platform, or distribution capability than in the original BUPAP brand.

FAQs

Can BUPAP be reformulated with common pharmaceutical excipients?

Yes. A new immediate-release formulation can use standard tablet excipients, provided it meets FDA requirements for quality, inactive-ingredient acceptability, dissolution, stability, and bioequivalence.

Would a new BUPAP tablet automatically receive new patent protection?

No. Standard excipient substitutions generally lack the novelty and non-obviousness needed for meaningful patent protection. Patent value requires a technically differentiated composition or process supported by comparative data.

Is an extended-release BUPAP product commercially attractive?

It could provide differentiation, but it would introduce substantial regulatory and safety complexity. Altering butalbital exposure may affect sedation, dependence risk, bioequivalence, and labeling.

Can packaging reduce the acetaminophen overdose risk?

Packaging can reduce accidental duplicate dosing and improve instructions, but it cannot eliminate toxicity from excessive total acetaminophen intake.

Is BUPAP a biosimilar opportunity?

No. BUPAP is a small-molecule oral combination product. Competitive entry occurs through generic-drug pathways, not biosimilar approval.

References

1. U.S. Food and Drug Administration. (n.d.). BUPAP- butalbital and acetaminophen tablet: Prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
3. U.S. Food and Drug Administration. (2015). Abbreviated new drug application submissions: Refuse-to-receive standards. FDA. https://www.fda.gov/
4. U.S. Food and Drug Administration. (2017). FDA’s guidance for industry: General principles for evaluating abuse-deterrent formulations of opioid drugs. FDA. https://www.fda.gov/
5. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
6. U.S. Food and Drug Administration. (n.d.). Acetaminophen information. FDA. https://www.fda.gov/drugs/information-drug-class/acetaminophen-information-